Reasonable use of corticosteroids in chronic inflammatory bowel disease;Pour un usage raisonné des corticoïdes dans les maladies inflammatoires chroniques de l'intestin

Hepato-Gastro

Volumn 11, Issue 3, 2004, Pages 189-195

  Lémann, Marc ^a   Gornet, Jean Marc ^a   Allez, Matthieu ^a   Nachury, Maria ^a  

^a SAINT LOUIS HOSPITAL   (France)

Author keywords

[No Author keywords available]

Indexed keywords

AZATHIOPRINE; BETAMETHASONE SODIUM PHOSPHATE; BUDESONIDE; CORTICOSTEROID; CYCLOSPORIN; HYDROCORTISONE; INFLIXIMAB; PREDNISOLONE 3 SULFOBENZOATE; PREDNISONE;

ARTIFICIAL FEEDING; CLINICAL TRIAL; CORTICOSTEROID THERAPY; DRUG DEPENDENCE; DRUG DOSE REGIMEN; DRUG EFFICACY; DRUG USE; ENTERITIS; HUMAN; IMMUNOSUPPRESSIVE TREATMENT; SHORT SURVEY;

EID: 2642557824     PISSN: 12537020     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Short Survey

References (34)

1. Present DH. How to do without steroids in inflammatory bowel disease. Inflam Bowel Dis 2000; 6: 48-57.
2. Modigliani R, Mary JY, Simon JF, Cortot A, Soulé JC, Gendre JP, et al. and the Groupe d'étude thérapeutique des affections inflammatoires digestives (Getaid). Clinical, biological, and endoscopic picture of attacks of Crohn's disease. Gastroenterology 1990; 98: 811-8.
3. Landi B, Anh TN, Cortot A, Soule JC, Rene E, Gendre JP, et al. and the Groupe d'études thérapeutiques des affections inflammatoires digestives (Getaid). Endoscopic monitoring of Crohn's disease treatment: a prospective, randomized clinical trial. Gastroenterology 1992; 102: 1647-53.
4. Modigliani R, Colombel JF, Dupas JL, Dapoigny M, Costil V, Veyrac M, et al. Mesalamine in Crohn's disease with steroid-induced remission: effect on steroid withdrawal and remission maintenance, Groupe d'études thérapeutiques des affections inflammatoires digestives. Gastroenterology 1996; 110: 688-93.
5. Summers RW, Switz DM, Sessions JT, Becktel JM, Best WR, Kern F, et al. National Cooperative Crohn's Disease Study: results of drug treatment. Gastroenterology 1979; 77: 847-69.
6. Rutgeerts P, Lofberg R, Malchow H, Lamers C, Olaison G, Jewell D, et al. A comparison of budesonide with prednisolone for active Crohn's disease. N Engl J Med 1994; 331: 842-5.
7. Campieri M, Ferguson A, Doe W, Persson T, Nilsson LG, and the Global Budesonide Study Group. Oral budesonide is as effective as oral prednisolone in active Crohn's disease. Gut 1997; 41: 209-14.
8. Truelove SC, Witts U. Cortisone in ulcerative colitis; final report on a therapeutic trial. Br Med J 1955; 9: 1041-8.
9. Thomsen OO, Cortot A, Jewell D, Wright JP, Winter T, Veloso FT, et al. for the International Budesonide-Mesalamine Study Group. A comparison of budesonide and mesalamine for active Crohn's disease. N Engl J Med 1998; 339: 370-4.
10. Truelove SC, Watkinson G, Draper G. Comparison of corticosteroid and sulphasalazine therapy in ulcerative colitis. Br Med J 1962; 5321: 1708-11.
11. Lochs H, Steinhardt HJ, Klaus-Wentz B, Zeitz M, Vogelsang H, Sommer H, et al. Comparison of enteral nutrition and drug treatment in active Crohn's disease. Results of a European Cooperative Crohn's Disease Study IV. Gastroenterology 1991; 101: 881-8.
12. D'Haens G, Lemmens L, Geboes K, Vandeputte L, Van Acker F, Mortelmans L, et al. Intravenous cyclosporine versus intravenous corticosteroids as single therapy for severe attacks of ulcerative colitis. Gastroenterology 2001; 120: 1323-9.
13. Brignola C, De Somone G, Belloli C, Iannone P, Belluzi A, Gionchetti P, et al. Steroid treatment in active Crohn's disease: a comparison between two regimens of different duration. Aliment Pharmacol Ther 1994; 8: 465-8.
14. Greenberg GR, Feagan BG, Martin F, Sutherland LR, Thomson AB, Williams CN, et al. and the Canadian Inflammatory Bowel Disease Study Group. Oral budesonide for active Crohn's disease. N Engl J Med 1994; 331: 836-41.
15. Gross V, Andus T, Caesar I, Bischoff SC, Lochs H, Tromm A, et al. for the German/Austria Budesonide Study Group. Oral pH-modified release budesonide versus 6-methyl-prednisolone in active Crohn's disease. Eur J Gastroenterol Hepatol 1996; 8: 905-9.
16. Bar-Meir S, Chowers Y, Lavy A, Abromovitch D, Sternberg A, Leichtmann G, et al. and the Israeli Budesonide-Mesalamine Study Group. Budesonide versus prednisone in the treatment of active Crohn's disease. Gastroenterology 1998; 115: 835-40.
17. Papi C, Luchetti R, Gili L, Montanti S, Koch M, Carpurso L. Budesonide in the treatment of Crohn's disease: a meta-analysis. Aliment Pharmacol Ther 2000; 14: 1419-28.
18. Steinhart AH, Ewe K, Griffiths AM, Modigliani R, Thomsen OO. Corticosteroids for maintaining remission of Crohn's disease. The Cochrane Library 2001, 4. Oxford: Update Software.
19. Cortot A, Colombel JF, Rutgeerts P, Lauritsen K, Malchow H, Hamling J, et al. Switch from systemic steroids to budesonide in steroid dependent patients with inactive Crohn's disease. Gut 2001; 48: 186-90.
20. Lofberg R, Rutgeerts P, Malchow H, Lamers C, Danielsson A, Olaison G, et al. Budesonide prolongs time to relapse in ileal and ileocaecal Crohn's disease: a placebo controlled one year study. Gut 1996; 39: 82-6.
21. Greenberg GR, Feagan BG, Martin F, Sutherland LR, Thomson AB, Williams CN, et al. Oral budesonide as maintenance treatment for Crohn's disease: a placebo-controlled, dose-ranging study. Canadian Inflammatory Bowel Disease Study Group. Gastroenterology 1996; 110: 45-51.
22. Ferguson A, Campieri M, Doe W, Persson T, Nygard G. Oral budesonide as maintenance therapy in Crohn's disease - results of a 12-month study. Global Budesonide Study Group. Aliment Pharmacol Ther 1998; 12: 175-83.
23. Gross V, Andus T, Ecker KW, Raedler A, Loeschke K, Plauth M, et al. Low dose oral pH modified release budesonide for maintenance of steroid induced remission in Crohn's disease. The Budesonide Study Group. Gut 1998; 42: 493-6.
24. Cino M, Greenberg GR. Bone mineral density in Crohn's disease: a longitudinal study of budesonide, prednisone, and nonsteroid therapy. Am J Gastroenterol 2002; 97: 915-21.
25. Stockbrugger RW, Schoon E, Bollani S, Israeli E, Persson T, Bengtsson B, et al. Budesonide versus prednisolone in the management of Crohn's disease: a randomized multi-national 2-year study. Gastroenterology 2003; 124: A181.
26. Modigliani R. Les formes corticorésistantes et corticodépendantes de la maladie de Crohn. Gastroenterol Clin Biol 1987; 11: 473-6.
27. Munkolm P, Langholz E, Davidsen M, Binder V. Frequency of glucocorticoid resistance and dependency in Crohn's disease. Gut 1994; 35: 360-2.
28. Faubion WA Jr, Loftus EV Jr, Harmsen WS, Zinsmeister AR, Sandborn WJ. The natural history of corticosteroid therapy for inflammatory bowel disease: a population-based study. Gastroenterology 2001; 121: 255-60.
29. Lémann M, Colombel JF, Duclos B, Veyrac M, Dupas JL, Delchier JC, et al. Infliximab in steroid dependent Crohn's disease patients treated with azathioprine or 6-MP: a randomized double-blind placebo controlled trial. Gastroenterology 2003; last breaking session.
30. Mantzaris GJ, Petraki K, Chadio-Iordanides H, Christidou A, Karragiannidis A, Glarakis J, et al. Maintenance therapy with azathioprine is superior to budesonide in healing endoscopic lesions and improving histology in clinically quiescent Crohn's disease. Gastroenterology 2002; 122: A135.
31. D'Haens G, van Deventer S, van Hogezand R, Chalmers D, Braakman T, Schaible T, et al. Endoscopic healing with infliximab anti-tumor necrosis factor antibodies in Crohn's disease: a European multicenter trial. Gastroenterology 1999; 116: 1029-34.
32. Lémann M, Bouhnik Y, Colombel JF, Duclos B, Soule JC, Lerebours E, et al. Randomized, double-blind, placebo controlled, multicenter, azathioprine withdrawal trial in Crohn's disease. Gastroenterology 2002; 122: A34.
33. Riley SA, Mani V, Goodman MJ, Dutt S, Herd ME. Microscopic activity in ulcerative colitis: what does it mean ? Gut 1991; 32: 174-8.
34. Bernstein CN, Leslie WD, Leboff MS. AGA technical review on osteoporosis in gastrointestinal diseases. Gastroenterology 2003; 124: 795-841.